Boston Scientific Corp (BSX)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $64.27B
Last updated: Nov 17, 2026 at 11:05 AM ET
Boston Scientific Corp (BSX) Stock Forecast
Analysts expect Boston Scientific (BSX) to earn $3.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $20.97B. Of 31 analysts, 20 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.13.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 31 ratings average 2.16, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 65% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 6 | 19.4% |
| Buy | 14 | 45.2% |
| Hold | 11 | 35.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 31
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 1.3% and revenue estimates fall 0.4%.
- Fiscal year ending Dec 31, 2026
- $3.17
- EPS consensus, revenue $20.97B
- Fiscal year ending Dec 31, 2027
- $3.13
- EPS consensus, revenue $20.88B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.17 | $3.15 to $3.29 | 28 | $20.97B | $20.90B to $21.10B | 28 |
| Dec 31, 2027 | $3.13 | $3.02 to $3.45 | 28 | $20.88B | $20.44B to $22.50B | 28 |
Quarterly Estimates
The EPS consensus falls from $0.78 for the quarter ending Dec 31, 2026 to $0.74 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.78 | $0.74 to $0.83 | 26 | $5.23B | $5.04B to $5.51B | 26 |
| Mar 31, 2027 | $0.74 | $0.70 to $0.78 | 16 | $5.06B | $4.94B to $5.14B | 15 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 36 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 0 | 26 |
| Quarter ending Mar 31, 2027 | 0 | 10 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.9% from $3.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.17 | $3.17 | $3.25 | $3.29 | $3.30 | -4.0% |
| Fiscal year ending Dec 31, 2027 | $3.13 | $3.13 | $3.38 | $3.43 | $3.44 | -9.0% |
| Quarter ending Mar 31, 2027 | $0.74 | $0.80 | $0.80 | $0.80 | $0.80 | -7.2% |
Frequently Asked Questions About BSX
What is the BSX stock forecast?
Consensus analyst estimates put Boston Scientific's EPS at $3.17 for the fiscal year ending Dec 31, 2026, on revenue of $20.97B. The consensus rating from 31 analysts is Buy.
How do analysts rate BSX stock?
Of 31 analysts covering Boston Scientific, 6 rate it Strong Buy, 14 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BSX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.17, with estimates from $3.15 to $3.29 from 28 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $3.02 to $3.45 from 28 analysts.
What revenue do analysts expect from Boston Scientific next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $20.97B, with estimates from $20.90B to $21.10B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.88B, with estimates from $20.44B to $22.50B.
How many analysts cover BSX?
31 analysts rate Boston Scientific stock, and 28 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BSX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts